Merck has partnered with Isomorphic Labs to discover small-molecule oncology candidates for an undisclosed strategic target. Under the research collaboration, Isomorphic provides its proprietary drug design engine and leverages Merck’s wet-lab data, while Merck retains responsibility for preclinical and clinical development, manufacturing, and commercialization. The collaboration signals a continuation of major pharma adopting AI simulation platforms to shorten early discovery cycles and improve target-to-lead progression. Because the target is not disclosed, near-term read-through will focus on how quickly Merck can generate internally validated candidates and whether the partnership accelerates IND-enabling work. For the broader sector, the deal also suggests that the highest-value AI platforms are those that combine modeling with partner experimental datasets to improve relevance and reduce iteration costs. (Story context: this collaboration follows Isomorphic’s recent capital raise.)